Clinical Trials Browser

Available × Myeloid × Clear all

NCT06915766 2026-05-08

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT05593185 2026-04-24

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07215832 2026-03-02

KEAP

GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT04360005 2025-12-05

Managed Access Programs for ABL001, Asciminib

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01881334 2025-11-20

Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Adrenoleukodystrophy, Anemia, Aplastic, Anemia, Sickle Cell, Immunologic Deficiency Syndromes, Lymphoma, Metabolic Diseases, Myelodysplastic Syndromes, Thalassemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04745637 2025-11-18

Managed Access Programs for INC424, Ruxolitinib

Polycythemia Vera, Primary Myelofibrosis

NCT00854841 2009-03-03

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive